{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T19:09:04Z","timestamp":1743016144648,"version":"3.40.3"},"publisher-location":"Cham","reference-count":185,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030716967"},{"type":"electronic","value":"9783030716974"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-71697-4_14","type":"book-chapter","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T08:03:45Z","timestamp":1626681825000},"page":"169-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19)"],"prefix":"10.1007","author":[{"given":"Victor B.","family":"Hsue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Itamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa A.","family":"Illing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Sokoloski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bree A.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan Y.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/JCMA.0000000000000270","volume":"83","author":"YC Wu","year":"2020","unstructured":"Wu YC, Chen CS, Chan YJ (2020) The outbreak of COVID-19: an overview. J Chin Med Assoc 83:217\u2013220","journal-title":"J Chin Med Assoc"},{"key":"14_CR2","doi-asserted-by":"publisher","unstructured":"Liu X, Zhang S (2020) COVID-19: face masks and human-to-human transmission. Influenza Other Respir Viruses. https:\/\/doi.org\/10.1111\/irv.12740","DOI":"10.1111\/irv.12740"},{"issue":"5","key":"14_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00417-020-04652-5","volume":"258","author":"C Yang","year":"2020","unstructured":"Yang C (2020) Does hand hygiene reduce SARS-CoV-2 transmission? Graefes Arch Clin Exp Ophthalmol 258(5):1133\u20131134","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"14_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00417-020-04653-4","volume":"258","author":"THT Lai","year":"2020","unstructured":"Lai THT, Tang EWH, Fung KSC, Li KKW (2020) Reply to \u201cdoes hand hygiene reduce SARS-CoV-2 transmission?\u201d. Graefes Arch Clin Exp Ophthalmol 258(5):1135. https:\/\/doi.org\/10.1007\/s00417-020-04653-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"14_CR5","unstructured":"Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) Features, evaluation, and treatment of coronavirus. In: StatPearls. StatPearls Publishing, Treasure Island. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/"},{"issue":"4","key":"14_CR6","doi-asserted-by":"publisher","first-page":"e00028","DOI":"10.1128\/CMR.00028-20","volume":"33","author":"K Dhama","year":"2020","unstructured":"Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS et al (2020) Coronavirus disease 2019\u2013COVID-19. Microbiol Rev 33(4):e00028\u2013e00020. https:\/\/doi.org\/10.1128\/CMR.00028-20","journal-title":"Microbiol Rev"},{"issue":"12","key":"14_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMc2001737","volume":"382","author":"L Zou","year":"2020","unstructured":"Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z et al (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382(12):1177\u20131179. https:\/\/doi.org\/10.1056\/NEJMc2001737","journal-title":"N Engl J Med"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"104821","DOI":"10.1016\/j.oraloncology.2020.104821","volume":"108","author":"M Baghizadeh Fini","year":"2020","unstructured":"Baghizadeh Fini M (2020) Oral saliva and COVID-19. Oral Oncol 108:104821. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104821","journal-title":"Oral Oncol"},{"issue":"6","key":"14_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41368-020-0080-z","volume":"12","author":"R Xu","year":"2020","unstructured":"Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q (2020) Saliva: potential diagnostic value and transmission of 2019-nCoV. Int J Oral Sci 12(6):11. https:\/\/doi.org\/10.1038\/s41368-020-0080-z","journal-title":"Int J Oral Sci"},{"issue":"9","key":"14_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/M20-0504","volume":"172","author":"SA Lauer","year":"2020","unstructured":"Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR et al (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 172(9):577\u2013582","journal-title":"Ann Intern Med"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fmed.2020.00334","volume":"7","author":"H Wang","year":"2020","unstructured":"Wang H, Liu Q, Hu J, Zhou M, Yu MQ, Li KY et al (2020) Nasopharyngeal swabs are more sensitive than oropharyngeal swabs for COVID-19 diagnosis and monitoring the SARS-CoV-2 load. Front Med 7:334. https:\/\/doi.org\/10.3389\/fmed.2020.00334","journal-title":"Front Med"},{"key":"14_CR12","doi-asserted-by":"crossref","unstructured":"Ascenzi JM (1996) Handbook of disinfectants and antiseptics. CRC Press, Boca Raton. ISBN-13: 978-0824795245","DOI":"10.1201\/9781482273359"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1017\/S0950268820002319","volume":"148","author":"D Singh","year":"2020","unstructured":"Singh D, Joshi K, Samuel A, Patra J, Mahindroo N (2020) Alcohol-based hand sanitisers as first line of defence against SARS-CoV-2: a review of biology, chemistry and formulations. Epidemiol Infect 148:e229. https:\/\/doi.org\/10.1017\/S0950268820002319","journal-title":"Epidemiol Infect"},{"key":"14_CR14","unstructured":"World Health Organization Guide to Local Production: WHO-recommended handrub formulations. https:\/\/www.who.int\/gpsc\/5may\/Guide_to_Local_Production.pdf?ua=1. Accessed 20 Oct 2020"},{"key":"14_CR15","unstructured":"CDC (2020) Coronavirus disease 2019 (COVID-19). In: Centers for disease control and prevention. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/hand-hygiene.html. Accessed 31 Oct 2020"},{"issue":"6","key":"14_CR16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/infdis\/jix046","volume":"215","author":"A Siddharta","year":"2017","unstructured":"Siddharta A, Pfaender S, Vielle NJ, Dijkman R, Friesland M, Becker B et al (2017) Virucidal activity of World Health Organization\u2013recommended formulations against enveloped viruses, including Zika, Ebola, and Emerging Coronaviruses. J Infect Dis 215(6):902\u2013906","journal-title":"J Infect Dis"},{"issue":"2","key":"14_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhin.2004.12.023","volume":"61","author":"HF Rabenau","year":"2005","unstructured":"Rabenau HF, Kampf G, Cinatl J, Doerr HW (2005) Efficacy of various disinfectants against SARS coronavirus. J Hosp Infect 61(2):107\u2013111","journal-title":"J Hosp Infect"},{"key":"14_CR18","doi-asserted-by":"publisher","unstructured":"Hirose R, Ikegaya H, Naito Y, Watanabe N, Yoshida T, Bandou R et al (2020) Survival of SARS-CoV-2 and influenza virus on the human skin: importance of hand hygiene in COVID-19. Clin Infect Dis:ciaa1517. https:\/\/doi.org\/10.1093\/cid\/ciaa1517. Online ahead of print","DOI":"10.1093\/cid\/ciaa1517"},{"issue":"7","key":"14_CR19","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3201\/eid2607.200915","volume":"26","author":"A Kratzel","year":"2020","unstructured":"Kratzel A, Todt D, V\u2019kovski P, Steiner S, Gultom M, Thao TTN et al (2020) Inactivation of severe acute respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations and alcohols. Emerg Infect Dis 26(7):1592\u20131595","journal-title":"Emerg Infect Dis"},{"key":"14_CR20","doi-asserted-by":"publisher","unstructured":"Leslie RA, Zhou SS, Macinga DR (2020) Inactivation of SARS-CoV-2 by commercially available alcohol-based hand sanitizers. Am J Infect Control:S0196--6553(20)30804-X. https:\/\/doi.org\/10.1016\/j.ajic.2020.08.020. Online ahead of print","DOI":"10.1016\/j.ajic.2020.08.020"},{"issue":"8","key":"14_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ajic.2014.04.008","volume":"42","author":"LL Steed","year":"2014","unstructured":"Steed LL, Costello J, Lohia S, Jones T, Spannhake EW, Nguyen S (2014) Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic. Am J Infect Control 42(8):841\u2013846","journal-title":"Am J Infect Control"},{"issue":"12","key":"14_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1017\/ice.2019.266","volume":"40","author":"A Kanwar","year":"2019","unstructured":"Kanwar A, Kumar JA, Ng-Wong YK, Thakur M, Cadnum JL, Alhmidi H et al (2019) Evaluation of an alcohol-based antiseptic for nasal decolonization of methicillin-resistant Staphylococcus aureus in colonized patients. Infect Control Hosp Epidemiol 40(12):1436\u20131437","journal-title":"Infect Control Hosp Epidemiol"},{"key":"14_CR23","doi-asserted-by":"publisher","unstructured":"Meyers C, Robison R, Milici J, Alam S, Quillen D, Goldenberg D et al (2020) Lowering the transmission and spread of human coronavirus. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.26514. Online ahead of print","DOI":"10.1002\/jmv.26514"},{"issue":"8","key":"14_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/infdis\/jiaa471","volume":"222","author":"TL Meister","year":"2020","unstructured":"Meister TL, Br\u00fcggemann Y, Todt D, Conzelmann C, M\u00fcller JA, Gro\u00df R et al (2020) Virucidal efficacy of different oral rinses against severe acute respiratory syndrome coronavirus 2. J Infect Dis 222(8):1289\u20131292","journal-title":"J Infect Dis"},{"key":"14_CR25","unstructured":"Antiseptic Mouthwash \/ Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) \u2013 ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04409873. Accessed 31 Oct 2020"},{"issue":"9","key":"14_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1177\/0145561320932318","volume":"99","author":"S Frank","year":"2020","unstructured":"Frank S, Capriotti J, Brown SM, Tessema B (2020) Povidone-iodine use in sinonasal and oral cavities: a review of safety in the COVID-19 era. Ear Nose Throat J 99(9):586\u2013593","journal-title":"Ear Nose Throat J"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1743-422X-6-124","volume":"6","author":"N Sriwilaijaroen","year":"2009","unstructured":"Sriwilaijaroen N, Wilairat P, Hiramatsu H, Takahashi T, Suzuki T, Ito M et al (2009) Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J 6:124. https:\/\/doi.org\/10.1186\/1743-422X-6-124","journal-title":"Virol J"},{"issue":"2","key":"14_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40121-018-0200-7","volume":"7","author":"M Eggers","year":"2018","unstructured":"Eggers M, Koburger-Janssen T, Eickmann M, Zorn J (2018) In vitro bactericidal and virucidal efficacy of povidone-iodine gargle\/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther 7(2):249\u2013259","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"14_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000089211","volume":"1","author":"H Kariwa","year":"2006","unstructured":"Kariwa H, Fujii N, Takashima I (2006) Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology 212 Suppl 1(Suppl 1):119\u2013123","journal-title":"Dermatology 212 Suppl"},{"key":"#cr-split#-14_CR30.1","unstructured":"3M (2016) Safety & Efficacy Information"},{"key":"#cr-split#-14_CR30.2","unstructured":"3MTM Skin and Nasal Antiseptic. https:\/\/multimedia.3m.com\/mws\/media\/716788O\/3m-skin-and-nasal-antiseptic-safety-and-efficacy-brochure.pdf. Accessed 31 Oct 2020"},{"key":"14_CR31","doi-asserted-by":"publisher","unstructured":"Frank S, Brown SM, Capriotti JA, Westover JB, Pelletier JS, Tessema B (2020) In vitro efficacy of a povidone-iodine nasal Antiseptic for rapid inactivation of SARS-CoV-2. JAMA Otolaryngol Head Neck Surg. Sep 17:e203053. https:\/\/doi.org\/10.1001\/jamaoto.2020.3053. Online ahead of print","DOI":"10.1001\/jamaoto.2020.3053"},{"issue":"6","key":"14_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/jopr.13209","volume":"29","author":"AS Bidra","year":"2020","unstructured":"Bidra AS, Pelletier JS, Westover JB, Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B (2020) Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine Oral antiseptic rinse. J Prosthodont 29(6):529\u2013533","journal-title":"J Prosthodont"},{"key":"14_CR33","doi-asserted-by":"crossref","unstructured":"Kirk-Bayley J (2020) A pilot study of the ability of povidone-iodine (PVP-I) 0\u20225% aqueous solution oral\/nasal spray and mouthwash to kill the SARS-CoV-2 virus. http:\/\/www.isrctn.com\/ISRCTN13447477. Accessed 31 Oct 2020","DOI":"10.1186\/ISRCTN13447477"},{"key":"14_CR34","unstructured":"Khan FR (2020) A clinical trial of gargling agents in reducing intraoral viral load among COVID-19 patients (GARGLES). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341688. Accessed 31 Oct 2020"},{"key":"14_CR35","unstructured":"Friedland P (2020) Virucidal pilot study of Nasodine\u00ae Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus. https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12620000470998. Accessed 31 Oct 2020"},{"key":"14_CR36","unstructured":"Kejner A (2020) Povidone-iodine intranasal for prophylaxis in front-line health-care personnel and inpatients during the sars-CoV-2 pandemic. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04364802. Accessed 31 Oct 2020"},{"issue":"4","key":"14_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12663-016-0976-5","volume":"16","author":"A Managutti","year":"2017","unstructured":"Managutti A, Managutti SA, Patel J, Puthanakar NY (2017) Evaluation of post-surgical bacteremia with use of povidone-iodine and chlorhexidine during mandibular third molar surgery. J Maxillofac Oral Surg 16(4):485\u2013490","journal-title":"J Maxillofac Oral Surg"},{"issue":"Suppl 1","key":"14_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000057722","volume":"204","author":"T Nagatake","year":"2002","unstructured":"Nagatake T, Ahmed K, Oishi K (2002) Prevention of respiratory infections by povidone-iodine gargle. Dermatology 204(Suppl 1):32\u201336","journal-title":"Dermatology"},{"issue":"9","key":"14_CR39","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1016\/j.arth.2017.04.039","volume":"32","author":"M Rezapoor","year":"2017","unstructured":"Rezapoor M, Nicholson T, Tabatabaee RM, Chen AF, Maltenfort MG, Parvizi J (2017) Povidone-iodine-based solutions for decolonization of nasal Staphylococcus aureus: a randomized, prospective, placebo-controlled study. J Arthroplast 32(9):2815\u20132819","journal-title":"J Arthroplast"},{"issue":"Suppl 1","key":"14_CR40","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1017\/S0022215114002746","volume":"129","author":"JH Kim","year":"2015","unstructured":"Kim JH, Rimmer J, Mrad N, Ahmadzada S, Harvey RJ et al (2015) Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol 129(Suppl 1):S45\u2013S50","journal-title":"J Laryngol Otol"},{"key":"14_CR41","doi-asserted-by":"publisher","unstructured":"Ramezanpour M, Smith JLP, Psaltis AJ, Wormald PJ, Vreugde S (2020) In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells. Int Forum Allergy Rhinol. Apr 6. https:\/\/doi.org\/10.1002\/alr.22575. Online ahead of print","DOI":"10.1002\/alr.22575"},{"issue":"Suppl 2","key":"14_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000246034","volume":"195","author":"K Nobukuni","year":"1997","unstructured":"Nobukuni K, Hayakawa N, Namba R, Ihara Y, Sato K, Takada H et al (1997) The influence of long-term treatment with povidone-iodine on thyroid function. Dermatology 195(Suppl 2):69\u201372","journal-title":"Dermatology"},{"issue":"9","key":"14_CR43","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s004310000496","volume":"159","author":"K Casteels","year":"2000","unstructured":"Casteels K, P\u00fcnt S, Br\u00e4mswig J (2000) Transient neonatal hypothyroidism during breastfeeding after post-natal maternal topical iodine treatment. Eur J Pediatr 159(9):716\u2013717","journal-title":"Eur J Pediatr"},{"key":"14_CR44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3389\/fmicb.2020.01351","volume":"11","author":"G Dev Kumar","year":"2020","unstructured":"Dev Kumar G, Mishra A, Dunn L, Townsend A, Oguadinma IC, Bright KR et al (2020) Biocides and novel antimicrobial agents for the mitigation of coronaviruses. Front Microbiol 11:1351. https:\/\/doi.org\/10.3389\/fmicb.2020.01351","journal-title":"Front Microbiol"},{"issue":"4","key":"14_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhin.2014.02.003","volume":"86","author":"SM Goyal","year":"2014","unstructured":"Goyal SM, Chander Y, Yezli S, Otter JA (2014) Evaluating the virucidal efficacy of hydrogen peroxide vapour. J Hosp Infect 86(4):255\u2013259","journal-title":"J Hosp Infect"},{"issue":"4","key":"14_CR46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1834-7819.2000.tb00261.x","volume":"45","author":"LJ Walsh","year":"2000","unstructured":"Walsh LJ (2000) Safety issues relating to the use of hydrogen peroxide in dentistry. Aust Dent J 45(4):257\u2013269","journal-title":"Aust Dent J"},{"issue":"1","key":"14_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41368-020-0075-9","volume":"12","author":"X Peng","year":"2020","unstructured":"Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B (2020) Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci 12(1):9. https:\/\/doi.org\/10.1038\/s41368-020-0075-9","journal-title":"Int J Oral Sci"},{"issue":"1","key":"14_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0030-4220(58)90228-7","volume":"11","author":"FW Kraus","year":"1958","unstructured":"Kraus FW, Perry WI, Nickerson JF (1958) Salivary catalase and peroxidase values in normal subjects and in persons with periodontal disease. Oral Surg Oral Med Oral Pathol 11(1):95\u2013102","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"11","key":"14_CR49","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1017\/ice.2020.170","volume":"41","author":"AA Caruso","year":"2020","unstructured":"Caruso AA, Del Prete A, Lazzarino AI, Capaldi R, Grumetto L (2020) Might hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection? Infect Control Hosp Epidemiol 41(11):1360\u20131361","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"14_CR50","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jhin.2020.01.022","volume":"104","author":"G Kampf","year":"2020","unstructured":"Kampf G, Todt D, Pfaender S, Steinmann E (2020) Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 104(3):246\u2013251","journal-title":"J Hosp Infect"},{"key":"14_CR51","doi-asserted-by":"publisher","unstructured":"Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B (2020) Comparison of in vitro inactivation of SARS CoV-2 with hydrogen peroxide and povidone-iodine oral antiseptic rinses. J Prosthodont. Jun 30. https:\/\/doi.org\/10.1111\/jopr.13220. Online ahead of print","DOI":"10.1111\/jopr.13220"},{"issue":"10","key":"14_CR52","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s00784-020-03549-1","volume":"24","author":"MJ Gottsauner","year":"2020","unstructured":"Gottsauner MJ, Michaelides I, Schmidt B, Scholz KJ, Buchalla W, Widbiller M et al (2020) A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. Clin Oral Investig 24(10):3707\u20133713","journal-title":"Clin Oral Investig"},{"key":"14_CR53","doi-asserted-by":"publisher","unstructured":"Ortega KL, Rech BO, El Haje GLC, Gallo CB, P\u00e9rez-Say\u00e1ns M, Braz-Silva PH (2020) Do hydrogen peroxide mouthwashes have a virucidal effect? A systematic review. J Hosp Infect. Oct 12;S0195-6701(20)30463-1. https:\/\/doi.org\/10.1016\/j.jhin.2020.10.003. Online ahead of print","DOI":"10.1016\/j.jhin.2020.10.003"},{"key":"14_CR54","doi-asserted-by":"publisher","unstructured":"Capetti AF, Borgonovo F, Morena V, Lupo A, Cossu MV, Passerini M et al (2020) Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers. J Med Virol. Sep 3. https:\/\/doi.org\/10.1002\/jmv.26485. Online ahead of print","DOI":"10.1002\/jmv.26485"},{"issue":"1","key":"14_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/003335491012500105","volume":"125","author":"NG Reed","year":"2010","unstructured":"Reed NG (2010) The history of ultraviolet germicidal irradiation for air disinfection. Public Health Rep 125(1):15\u201327","journal-title":"Public Health Rep"},{"issue":"14","key":"14_CR56","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1073\/pnas.90.14.6666","volume":"90","author":"RB Setlow","year":"1993","unstructured":"Setlow RB, Grist E, Thompson K, Woodhead AD (1993) Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci USA 90(14):6666\u20136670","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-3-319-56017-5_17","volume":"996","author":"S Roy","year":"2017","unstructured":"Roy S (2017) Impact of UV radiation on genome stability and human health. Adv Exp Med Biol 996:207\u2013219","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"14_CR58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/jop.2000.16.285","volume":"16","author":"D Balasubramanian","year":"2000","unstructured":"Balasubramanian D (2000) Ultraviolet radiation and cataract. J Ocul Pharmacol Ther 16(3):285\u2013297","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"14_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.taap.2003.08.019","volume":"195","author":"Y Matsumura","year":"2004","unstructured":"Matsumura Y, Ananthaswamy HN (2004) Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 195(3):298\u2013308","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"14_CR60","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/trf.13030","volume":"55","author":"SD Keil","year":"2015","unstructured":"Keil SD, Bengrine A, Bowen R, Marschner S, Hovenga N, Rouse L et al (2015) Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 55(7):1736\u20131744","journal-title":"Transfusion"},{"issue":"12","key":"14_CR61","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1111\/trf.13860","volume":"56","author":"SD Keil","year":"2016","unstructured":"Keil SD, Bowen R, Marschner S (2016) Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion 56(12):2948\u20132952","journal-title":"Transfusion"},{"issue":"6","key":"14_CR62","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/vox.12937","volume":"115","author":"SD Keil","year":"2020","unstructured":"Keil SD, Ragan I, Yonemura S, Hartson L, Dart NK, Bowen R (2020) Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang 115(6):495\u2013501","journal-title":"Vox Sang"},{"issue":"5","key":"14_CR63","doi-asserted-by":"publisher","first-page":"e0233947","DOI":"10.1371\/journal.pone.0233947","volume":"15","author":"I Ragan","year":"2020","unstructured":"Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R (2020) Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS One 15(5):e0233947. https:\/\/doi.org\/10.1371\/journal.pone.0233947","journal-title":"PLoS One"},{"issue":"7","key":"14_CR64","doi-asserted-by":"publisher","first-page":"e0236199","DOI":"10.1371\/journal.pone.0236199","volume":"15","author":"A Rezaie","year":"2020","unstructured":"Rezaie A, Leite GGS, Melmed GY, Mathur R, Villanueva-Millan MJ, Parodi G et al (2020) Ultraviolet A light effectively reduces bacteria and viruses including coronavirus. PLoS One 15(7):e0236199. https:\/\/doi.org\/10.1371\/journal.pone.0236199","journal-title":"PLoS One"},{"key":"14_CR65","unstructured":"Chaux G UVA light device to treat COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04572399. Accessed 1 Nov 2020"},{"issue":"3","key":"14_CR66","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaci.2004.11.005","volume":"115","author":"AI Koreck","year":"2005","unstructured":"Koreck AI, Csoma Z, Bodai L, Ignacz F, Kenderessy AS, Kadocsa E et al (2005) Rhinophototherapy: a new therapeutic tool for the management of allergic rhinitis. J Allergy Clin Immunol 115(3):541\u2013547","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"14_CR67","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1753465810374610","volume":"4","author":"C Cingi","year":"2010","unstructured":"Cingi C, Cakli H, Yaz A, Songu M, Bal C (2010) Phototherapy for allergic rhinitis: a prospective, randomized, single-blind, placebo-controlled study. Ther Adv Respir Dis 4(4):209\u2013213","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"14_CR68","first-page":"317","volume":"15","author":"S Alyasin","year":"2016","unstructured":"Alyasin S, Nabavizadeh SH, Houshmand H, Esmaeilzadeh H, Jelodar S, Amin R (2016) Short time efficiency of rhinophototherapy in management of patients with allergic rhinitis resistant to medical therapy. Iran J Allergy Asthma Immunol 15(4):317\u2013327","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"50","key":"14_CR69","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4193\/Rhino11.118","volume":"49","author":"SC Leong","year":"2011","unstructured":"Leong SC (2011) Rhinophototherapy: gimmick or an emerging treatment option for allergic rhinitis? Rhinology 49(50):499\u2013506","journal-title":"Rhinology"},{"issue":"2","key":"14_CR70","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4193\/Rhin16.063","volume":"55","author":"N Dulguerov","year":"2017","unstructured":"Dulguerov N, Guinand N, Courvoisier D, Landis BN, Lacroix JS, Hauser C (2017) Rhinophototherapy in chronic rhinosinusitis: a double blind randomized placebo-controlled trial. Rhinology 55(2):106\u2013112","journal-title":"Rhinology"},{"issue":"1","key":"14_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12903-017-0382-5","volume":"17","author":"A Takada","year":"2017","unstructured":"Takada A, Matsushita K, Horioka S, Furuichi Y, Sumi Y (2017) Bactericidal effects of 310 nm ultraviolet light-emitting diode irradiation on oral bacteria. BMC Oral Health 17(1):96. https:\/\/doi.org\/10.1186\/s12903-017-0382-5","journal-title":"BMC Oral Health"},{"issue":"2\u20133","key":"14_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jphotobiol.2007.09.013","volume":"89","author":"A Koreck","year":"2007","unstructured":"Koreck A, Szechenyi A, Morocz M, Cimpean A, Bella Z, Garaczi E et al (2007) Effects of intranasal phototherapy on nasal mucosa in patients with allergic rhinitis. J Photochem Photobiol B 89(2\u20133):163\u2013169","journal-title":"J Photochem Photobiol B"},{"issue":"1\u20132","key":"14_CR73","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1582-4934.2008.00442.x","volume":"14","author":"D Mitchell","year":"2010","unstructured":"Mitchell D, Paniker L, Sanchez G, Bella Z, Garaczi E, Szell M et al (2010) Molecular response of nasal mucosa to therapeutic exposure to broad-band ultraviolet radiation. J Cell Mol Med 14(1\u20132):313\u2013322","journal-title":"J Cell Mol Med"},{"issue":"17","key":"14_CR74","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1007\/s00253-020-10708-7","volume":"104","author":"A Gasmi Benahmed","year":"2020","unstructured":"Gasmi Benahmed A, Gasmi A, Arshad M, Shanaida M, Lysiuk R, Peana M et al (2020) Health benefits of xylitol. Appl Microbiol Biotechnol 104(17):7225\u20137237","journal-title":"Appl Microbiol Biotechnol"},{"issue":"10","key":"14_CR75","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.5005\/jp-journals-10024-2652","volume":"20","author":"M Hajiahmadi","year":"2019","unstructured":"Hajiahmadi M, Yegdaneh A, Homayoni A, Parishani H, Moshkelgosha H, Salari-Moghaddam R (2019) Comparative evaluation of efficacy of \u201cgreen tea\u201d and \u201cgreen tea with xylitol\u201d mouthwashes on the salivary streptococcus mutans and lactobacillus colony count in children: a randomized clinical trial. J Contemp Dent Pract 20(10):1190\u20131194","journal-title":"J Contemp Dent Pract"},{"issue":"7","key":"14_CR76","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1017\/S0022215114001340","volume":"128","author":"\u00d6 Sakallio\u011flu","year":"2014","unstructured":"Sakallio\u011flu \u00d6, G\u00fcven\u00e7 IA, Cingi C (2014) Xylitol and its usage in ENT practice. J Laryngol Otol 128(7):580\u2013585","journal-title":"J Laryngol Otol"},{"issue":"4","key":"14_CR77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.amjoto.2017.03.006","volume":"38","author":"L Lin","year":"2017","unstructured":"Lin L, Tang X, Wei J, Dai F, Sun G (2017) Xylitol nasal irrigation in the treatment of chronic rhinosinusitis. Am J Otolaryngol 38(4):383\u2013389","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"14_CR78","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1248\/bpb.b15-00773","volume":"39","author":"ML Xu","year":"2016","unstructured":"Xu ML, Wi GR, Kim HJ, Kim HJ (2016) Ameliorating effect of dietary xylitol on human respiratory syncytial virus (hRSV) infection. Biol Pharm Bull 39(4):540\u2013546","journal-title":"Biol Pharm Bull"},{"key":"14_CR79","doi-asserted-by":"publisher","unstructured":"Bansal S, Jonsson CB, Taylor SL, Figueroa JM, Dugour AV, Palacios C et al (2020) Iota-carrageenan and xylitol inhibit SARS-CoV-2 in cell culture. bioRxiv. https:\/\/doi.org\/10.1101\/2020.08.19.225854","DOI":"10.1101\/2020.08.19.225854"},{"key":"14_CR80","unstructured":"Westover JB (2020) Virucidal activity of Xlear compounds vs SARS-CoV-2 virus and rhinovirus-16. http:\/\/www.usu.edu\/iar. Accessed 31 Oct 2020"},{"key":"14_CR81","unstructured":"Tapparel C (2020) Antiviral activity of Xlear spray against SARS-CoV2. https:\/\/www.unige.ch\/medecine\/mimo\/en\/groupes\/953tapparel\/tapparel-vu-group-member\/caroline-tapparel-vu\/. Accessed 31 Oct 2020"},{"key":"14_CR82","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/fmb-2020-0048","volume":"15","author":"CL Matos de Opitz","year":"2020","unstructured":"Matos de Opitz CL, Sass P (2020) Tackling antimicrobial resistance by exploring new mechanisms of antibiotic action. Future Microbiol 15:703\u2013708","journal-title":"Future Microbiol"},{"issue":"9","key":"14_CR83","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1128\/AAC.02955-14","volume":"58","author":"B Mensa","year":"2014","unstructured":"Mensa B, Howell GL, Scott R, DeGrado WF (2014) Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58(9):5136\u20135145","journal-title":"Antimicrob Agents Chemother"},{"key":"14_CR84","unstructured":"Innovation Pharmaceuticals, Inc (2019) Phase 2 study to evaluate the efficacy & safety of brilacidin oral rinse administered daily for 7 weeks in attenuating oral mucositis in patients with head & neck cancer receiving chemoradiation. clinicaltrials.gov"},{"key":"14_CR85","unstructured":"Innovation Pharmaceuticals Reports Positive Topline Results from Phase 2 Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients. In: Innovation Pharmaceuticals Inc. http:\/\/www.ipharminc.com\/press-release\/2017\/12\/11\/innovation-pharmaceuticals-reports-positive-topline-results-from-phase-2-placebo-controlled-trial-of-brilacidin-for-the-prevention-of-oral-mucositis-in-head-and-neck-cancer-patients. Accessed 1 Nov 2020"},{"issue":"5","key":"14_CR86","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2020.1750595","volume":"29","author":"M Bassetti","year":"2020","unstructured":"Bassetti M, Del Puente F, Magnasco L, Giacobbe DR (2020) Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials. Expert Opin Investig Drugs 29(5):495\u2013506","journal-title":"Expert Opin Investig Drugs"},{"key":"14_CR87","unstructured":"Innovation Pharmaceuticals, Inc (2020) A phase 1, single dose escalation study to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers. clinicaltrials.gov"},{"key":"14_CR88","unstructured":"Cellceutix Corporation - Brilacidin-Otic. https:\/\/web.archive.org\/web\/20150408051410if_\/http:\/\/cellceutix.com\/brilacidin-otic\/#sthash.3BhoLfJG.daTZIyVS.dpbs. Accessed 1 Nov 2020"},{"issue":"1","key":"14_CR89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/jop.2015.0098","volume":"32","author":"RP Kowalski","year":"2016","unstructured":"Kowalski RP, Romanowski EG, Yates KA, Mah FS (2016) An independent evaluation of a novel peptide mimetic, Brilacidin (PMX30063), for ocular anti-infective. J Ocul Pharmacol Ther 32(1):23\u201327","journal-title":"J Ocul Pharmacol Ther"},{"key":"14_CR90","unstructured":"Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2. In: Innovation Pharmaceuticals Inc. http:\/\/www.ipharminc.com\/new-blog\/2020\/10\/30\/preprint-brilacidin-a-covid-19-drug-candidate-exhibits-potent-in-vitro-antiviral-activity-against-sars-cov-2. Accessed 1 Nov 2020"},{"key":"14_CR91","doi-asserted-by":"crossref","unstructured":"Bakovic A, Risner K, Bhalla N, et al (2020) Brilacidin, a COVID-19 drug candidate, exhibits potent in vitro antiviral activity against SARS-CoV-2. Microbiology","DOI":"10.1101\/2020.10.29.352450"},{"key":"14_CR92","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/00007435-199810000-00010","volume":"25","author":"RA Maguire","year":"1998","unstructured":"Maguire RA, Zacharopoulos VR, Phillips DM (1998) Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sex Transm Dis 25:494\u2013500","journal-title":"Sex Transm Dis"},{"issue":"7","key":"14_CR93","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1371\/journal.ppat.0020069","volume":"2","author":"CB Buck","year":"2006","unstructured":"Buck CB, Thompson CD, Roberts JN, M\u00fcller M, Lowy DR, Schiller JT (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2(7):e69. https:\/\/doi.org\/10.1371\/journal.ppat.0020069","journal-title":"PLoS Pathog"},{"key":"14_CR94","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1743-422X-5-107","volume":"5","author":"A Grassauer","year":"2008","unstructured":"Grassauer A, Weinmuellner R, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H (2008) Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virol J 5:107. https:\/\/doi.org\/10.1186\/1743-422X-5-107","journal-title":"Virol J"},{"issue":"12","key":"14_CR95","doi-asserted-by":"publisher","first-page":"e14320","DOI":"10.1371\/journal.pone.0014320","volume":"5","author":"A Leibbrandt","year":"2010","unstructured":"Leibbrandt A, Meier C, K\u00f6nig-Schuster M, Weinm\u00fcllner R, Kalthoff D, Pflugfelder B et al (2010) Iota-Carrageenan is a potent inhibitor of influenza a virus infection. PLoS One 5(12):e14320. https:\/\/doi.org\/10.1371\/journal.pone.0014320","journal-title":"PLoS One"},{"issue":"2","key":"14_CR96","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.antiviral.2012.05.009","volume":"95","author":"YH Chiu","year":"2012","unstructured":"Chiu YH, Chan YL, Tsai LW, Li TL, Wu CJ (2012) Prevention of human enterovirus 71 infection by kappa carrageenan. Antivir Res 95(2):128\u2013134","journal-title":"Antivir Res"},{"issue":"4","key":"14_CR97","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1185\/03007991003648015","volume":"26","author":"R Eccles","year":"2010","unstructured":"Eccles R, Martensson K, Chen SC (2010) Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Curr Med Res Opin 26(4):889\u2013899","journal-title":"Curr Med Res Opin"},{"key":"14_CR98","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1472-6882-12-147","volume":"12","author":"T Fazekas","year":"2012","unstructured":"Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C et al (2012) Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med 12:147. https:\/\/doi.org\/10.1186\/1472-6882-12-147","journal-title":"BMC Complement Altern Med"},{"issue":"1","key":"14_CR99","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1465-9921-14-124","volume":"14","author":"M Ludwig","year":"2013","unstructured":"Ludwig M, Enzenhofer E, Schneider S, Rauch M, Bodenteich A, Neumann K et al (2013) Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res 14(1):124. https:\/\/doi.org\/10.1186\/1465-9921-14-124","journal-title":"Respir Res"},{"issue":"1","key":"14_CR100","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/2049-6958-9-57","volume":"9","author":"M Koenighofer","year":"2014","unstructured":"Koenighofer M, Lion T, Bodenteich A, Prieschl-Grassauer E, Grassauer A, Unger H et al (2014) Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidiscip Respir Med 9(1):57. https:\/\/doi.org\/10.1186\/2049-6958-9-57","journal-title":"Multidiscip Respir Med"},{"key":"14_CR101","doi-asserted-by":"publisher","unstructured":"Kwon PS, Oh H, Kwon SJ, Jin W, Zhang F, Fraser K et al (2020) Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro 6:50. https:\/\/doi.org\/10.1038\/s41421-020-00192-8","DOI":"10.1038\/s41421-020-00192-8"},{"key":"14_CR102","unstructured":"Marinomed Biotech AG (2020) Study to investigate if sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to inactivate usual common cold viruses. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04533906. Accessed 31 Oct 2020"},{"issue":"1","key":"14_CR103","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1465-9921-8-38","volume":"8","author":"P Rennie","year":"2007","unstructured":"Rennie P, Bowtell P, Hull D, Charbonneau D, Lambkin-Williams R, J l O (2007) Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Respir Res 8(1):38. https:\/\/doi.org\/10.1186\/1465-9921-8-38","journal-title":"Respir Res"},{"issue":"8","key":"14_CR104","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1086\/512858","volume":"195","author":"JE Gern","year":"2007","unstructured":"Gern JE, Mosser AG, Swenson CA, Rennie PJ, England RJ, Shaffer J, Mizoguchi H (2007) Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis 195(8):1137\u20131143","journal-title":"J Infect Dis"},{"issue":"1","key":"14_CR105","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/S2666-5247(20)30003-3","volume":"1","author":"AWH Chin","year":"2020","unstructured":"Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen HL, Chan MCW et al (2020) Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe 1(1):e10. https:\/\/doi.org\/10.1016\/S2666-5247(20)30003-3","journal-title":"Lancet Microbe"},{"issue":"1","key":"14_CR106","doi-asserted-by":"publisher","first-page":"13630","DOI":"10.1038\/s41598-018-31936-y","volume":"8","author":"S Ramalingam","year":"2018","unstructured":"Ramalingam S, Cai B, Wong J, Twomey M, Chen R, Fu RM et al (2018) Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid levels. Sci Rep 8(1):13630. https:\/\/doi.org\/10.1038\/s41598-018-31936-y","journal-title":"Sci Rep"},{"issue":"1","key":"14_CR107","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41598-018-37703-3","volume":"9","author":"S Ramalingam","year":"2019","unstructured":"Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A (2019) A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci Rep 9(1):1015. https:\/\/doi.org\/10.1038\/s41598-018-37703-3","journal-title":"Sci Rep"},{"key":"14_CR108","unstructured":"University of Edinburgh (2020) Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04382131. Accessed 31 Oct 2020"},{"key":"14_CR109","doi-asserted-by":"publisher","unstructured":"Kimura KS, Freeman MH, Wessinger BC, Gupta V, Sheng Q, Huang LC et al Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019. Int Forum Allergy Rhinol. Sep 11. https:\/\/doi.org\/10.1002\/alr.22703. Online ahead of print","DOI":"10.1002\/alr.22703"},{"key":"14_CR110","unstructured":"King Faisal Specialist Hospital & Research Center (2020) HYPERTONIC SALINE COATED FACE MASK FOR REDUCING RESPIRATORY SYMPTOM SEVERITY IN PATIENTS WITH COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04465604. Accessed 31 Oct 2020"},{"issue":"9","key":"14_CR111","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamaoto.2020.1622","volume":"146","author":"NF Farrell","year":"2020","unstructured":"Farrell NF, Klatt-Cromwell C, Schneider JS (2020) Benefits and safety of nasal saline irrigations in a pandemic\u2014washing COVID-19 away. JAMA Otolaryngol Head Neck Surg 146(9):787\u2013788","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"14_CR112","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1945892418773566","volume":"32","author":"D Kanjanawasee","year":"2018","unstructured":"Kanjanawasee D, Seresirikachorn K, Chitsuthipakorn W, Snidvongs K (2018) Hypertonic saline versus isotonic saline nasal irrigation: systematic review and meta-analysis. Am J Rhinol Allergy 32(4):269\u2013279","journal-title":"Am J Rhinol Allergy"},{"issue":"7","key":"14_CR113","first-page":"475","volume":"57","author":"S Koelsch","year":"2007","unstructured":"Koelsch S, Tschaikin M, Sacher F (2007) Anti-rhinovirus-specific activity of the alpha-sympathomimetic oxymetazoline. Arzneimittelforschung 57(7):475\u2013482","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"14_CR114","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2500\/ajra.2010.24.3491","volume":"24","author":"B Winther","year":"2010","unstructured":"Winther B, Buchert D, Turner RB, Hendley JO, Tschaikin M (2010) Decreased rhinovirus shedding after intranasal oxymetazoline application in adults with induced colds compared with intranasal saline. Am J Rhinol Allergy 24(5):374\u2013377","journal-title":"Am J Rhinol Allergy"},{"key":"14_CR115","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.maturitas.2018.11.002","volume":"119","author":"N Dargahi","year":"2019","unstructured":"Dargahi N, Johnson J, Donkor O, Vasiljevic T, Apostolopoulos V (2019) Immunomodulatory effects of probiotics: can they be used to treat allergies and autoimmune diseases? Maturitas 119:25\u201338","journal-title":"Maturitas"},{"key":"14_CR116","doi-asserted-by":"crossref","unstructured":"Kassaa IA (2017) New insights on antiviral probiotics: from research to applications. Springer, New York. ISBN-13: 978-3319496870","DOI":"10.1007\/978-3-319-49688-7"},{"issue":"2","key":"14_CR117","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.intimp.2013.06.024","volume":"17","author":"E Chiba","year":"2013","unstructured":"Chiba E, Tomosada Y, Vizoso-Pinto MG, Salva S, Takahashi T, Tsukida K et al (2013) Immunobiotic Lactobacillus rhamnosus improves resistance of infant mice against respiratory syncytial virus infection. Int Immunopharmacol 17(2):373\u2013382","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"14_CR118","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1038\/s41598-019-39602-7","volume":"9","author":"K Eguchi","year":"2019","unstructured":"Eguchi K, Fujitani N, Nakagawa H, Miyazaki T (2019) Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep 9(1):4812. https:\/\/doi.org\/10.1038\/s41598-019-39602-7","journal-title":"Sci Rep"},{"issue":"10","key":"14_CR119","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1017\/S0007114513001104","volume":"110","author":"H Goto","year":"2013","unstructured":"Goto H, Sagitani A, Ashida N, Kato S, Hirota T, Shinoda T et al (2013) Anti-influenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br J Nutr 110(10):1810\u20131818","journal-title":"Br J Nutr"},{"issue":"1","key":"14_CR120","first-page":"6","volume":"51","author":"M Kawase","year":"2010","unstructured":"Kawase M, He F, Kubota A, Harata G, Hiramatsu M (2010) Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett Appl Microbiol 51(1):6\u201310","journal-title":"Lett Appl Microbiol"},{"issue":"2","key":"14_CR121","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.synbio.2018.03.001","volume":"3","author":"H Zhang","year":"2018","unstructured":"Zhang H, Yeh C, Jin Z, Ding L, Liu BY, Zhang L et al (2018) Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. Synth Syst Biotechnol 3(2):113\u2013120","journal-title":"Synth Syst Biotechnol"},{"key":"14_CR122","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41538-020-00078-9","volume":"4","author":"AN Olaimat","year":"2020","unstructured":"Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Abu Ghoush M, Al-Nabulsi AA et al (2020) The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. NPJ Sci Food 4:17. https:\/\/doi.org\/10.1038\/s41538-020-00078-9","journal-title":"NPJ Sci Food"},{"issue":"6","key":"14_CR123","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1472-765X.2010.02844.x","volume":"50","author":"G Harata","year":"2010","unstructured":"Harata G, He F, Hiruta N, Kawase M, Kubota A, Hiramatsu M et al (2010) Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses. Lett Appl Microbiol 50(6):597\u2013602","journal-title":"Lett Appl Microbiol"},{"key":"14_CR124","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2172-14-40","volume":"14","author":"Y Tomosada","year":"2013","unstructured":"Tomosada Y, Chiba E, Zelaya H, Takahashi T, Tsukida K, Kitazawa H et al (2013) Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol 14:40. https:\/\/doi.org\/10.1186\/1471-2172-14-40","journal-title":"BMC Immunol"},{"issue":"8","key":"14_CR125","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00011-015-0837-6","volume":"64","author":"H Zelaya","year":"2015","unstructured":"Zelaya H, Tada A, Vizoso-Pinto MG, Salva S, Kanmani P, Ag\u00fcero G et al (2015) Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation-coagulation interactions and reduces influenza virus-associated pulmonary damage. Inflamm Res 64(8):589\u2013602","journal-title":"Inflamm Res"},{"issue":"1","key":"14_CR126","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.antiviral.2011.11.004","volume":"93","author":"HN Youn","year":"2012","unstructured":"Youn HN, Lee DH, Lee YN, Park JK, Yuk SS, Yang SY et al (2012) Intranasal administration of live Lactobacillus species facilitates protection against influenza virus infection in mice. Antivir Res 93(1):138\u2013143","journal-title":"Antivir Res"},{"issue":"7","key":"14_CR127","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S2468-1253(20)30122-9","volume":"5","author":"JWY Mak","year":"2020","unstructured":"Mak JWY, Chan FKL, Ng SC (2020) Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol 5(7):644\u2013645","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"14_CR128","unstructured":"Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM) (2020) Randomised single blinded clinical study of efficacy of intranasal probiotic treatment to reduce severity of symptoms in COVID19 infection. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04458519. Accessed 31 Oct 2020"},{"key":"14_CR129","unstructured":"Bioithas SL (2020) The intestinal microbiota as a therapeutic target in hospitalized patients With COVID-19 infection. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04390477. Accessed 31 Oct 2020"},{"key":"14_CR130","unstructured":"Biosearch SA (2020) Multicentric study to assess the effect of consumption of lactobacillus coryniformis K8 on healthcare personnel exposed to COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04366180. Accessed 31 Oct 2020"},{"issue":"7","key":"14_CR131","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/jcpe.13127","volume":"46","author":"E Figuero","year":"2019","unstructured":"Figuero E, Herrera D, Tob\u00edas A, Serrano J, Rold\u00e1n S, Escribano M et al (2019) Efficacy of adjunctive anti-plaque chemical agents in managing gingivitis: a systematic review and network meta-analyses. J Clin Periodontol 46(7):723\u2013739","journal-title":"J Clin Periodontol"},{"issue":"3","key":"14_CR132","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1177\/00220345900690030901","volume":"69","author":"D Bernstein","year":"1990","unstructured":"Bernstein D, Schiff G, Echler G, Prince A, Feller M, Briner W (1990) In vitro virucidal effectiveness of a 0.12%-chlorhexidine gluconate mouthrinse. J Dent Res 69(3):874\u2013876","journal-title":"J Dent Res"},{"issue":"4","key":"14_CR133","first-page":"223","volume":"55","author":"N An","year":"2020","unstructured":"An N, Yue L, Zhao B (2020) Droplets and aerosols in dental clinics and prevention and control measures of infection. Zhonghua Kou Qiang Yi Xue Za Zhi 55(4):223\u2013228","journal-title":"Zhonghua Kou Qiang Yi Xue Za Zhi"},{"issue":"4","key":"14_CR134","first-page":"229","volume":"55","author":"J Su","year":"2020","unstructured":"Su J (2020) Aerosol transmission risk and comprehensive prevention and control strategy in dental treatments. Zhonghua Kou Qiang Yi Xue Za Zhi 55(4):229\u2013234","journal-title":"Zhonghua Kou Qiang Yi Xue Za Zhi"},{"issue":"20","key":"14_CR135","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.3346\/jkms.2020.35.e195","volume":"35","author":"JG Yoon","year":"2020","unstructured":"Yoon JG, Yoon J, Song JY, Yoon SY, Lim CS, Seong H et al (2020) Clinical significance of a high SARS-CoV-2 viral load in the saliva. J Korean Med Sci 35(20):e195. https:\/\/doi.org\/10.3346\/jkms.2020.35.e195","journal-title":"J Korean Med Sci"},{"key":"14_CR136","unstructured":"Dentaid SL (2020) Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado m\u00e9dico en Casa en Cali - 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04563689. Accessed 31 Oct 2020"},{"key":"14_CR137","unstructured":"Samanta A, Das G, Das S (2011) Roles of flavonoids in Plants. Int J Pharm Sci Technol 6:12\u201335. ISSN: 0975-0525"},{"key":"14_CR138","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1017\/jns.2016.41","volume":"5","author":"AN Panche","year":"2016","unstructured":"Panche AN, Diwan AD, Chandra SR (2016) Flavonoids: an overview. J Nutr Sci 5:e47. https:\/\/doi.org\/10.1017\/jns.2016.41. eCollection 2016","journal-title":"J Nutr Sci"},{"key":"14_CR139","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1054-3589(08)60983-7","volume":"38","author":"LG Korkina","year":"1997","unstructured":"Korkina LG, Afanas\u2019ev IB (1997) Antioxidant and chelating properties of flavonoids. Adv Pharmacol 38:151\u2013163","journal-title":"Adv Pharmacol"},{"issue":"1","key":"14_CR140","doi-asserted-by":"publisher","first-page":"16127","DOI":"10.1038\/s41598-017-16336-y","volume":"7","author":"JF Shimizu","year":"2017","unstructured":"Shimizu JF, Lima CS, Pereira CM, Bittar C, Batista MN, Nazar\u00e9 AC et al (2017) Flavonoids from pterogyne nitens inhibit hepatitis C virus entry. Sci Rep 7(1):16127. https:\/\/doi.org\/10.1038\/s41598-017-16336-y","journal-title":"Sci Rep"},{"issue":"22","key":"14_CR141","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.1016\/j.bmc.2010.09.035","volume":"18","author":"YB Ryu","year":"2010","unstructured":"Ryu YB, Jeong HJ, Kim JH, Kim YM, Park JY, Kim D et al (2010) Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem 18(22):7940\u20137947","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"14_CR142","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/cbdd.13604","volume":"94","author":"S Jo","year":"2019","unstructured":"Jo S, Kim H, Kim S, Shin DH, Kim MS (2019) Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem Biol Drug Des 94(6):2023\u20132030","journal-title":"Chem Biol Drug Des"},{"issue":"19","key":"14_CR143","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1016\/j.bmc.2009.08.036","volume":"17","author":"HJ Jeong","year":"2009","unstructured":"Jeong HJ, Ryu YB, Park SJ, Kim JH, Kwon HJ, Kim JH et al (2009) Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem 17(19):6816\u20136823","journal-title":"Bioorg Med Chem"},{"issue":"20","key":"14_CR144","doi-asserted-by":"publisher","first-page":"11334","DOI":"10.1128\/JVI.78.20.11334-11339.2004","volume":"78","author":"L Yi","year":"2004","unstructured":"Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G et al (2004) Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 78(20):11334\u201311339","journal-title":"J Virol"},{"issue":"3","key":"14_CR145","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11418-019-01287-7","volume":"73","author":"H Yan","year":"2019","unstructured":"Yan H, Ma L, Wang H, Wu S, Huang H, Gu Z et al (2019) Luteolin decreases the yield of influenza a virus in vitro by interfering with the coat protein I complex expression. J Nat Med 73(3):487\u2013496","journal-title":"J Nat Med"},{"issue":"2","key":"14_CR146","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/v12020184","volume":"12","author":"S Lalani","year":"2020","unstructured":"Lalani S, Poh CL (2020) Flavonoids as antiviral agents for Enterovirus A71 (EV-A71). Viruses 12(2):184. https:\/\/doi.org\/10.3390\/v12020184","journal-title":"Viruses"},{"key":"14_CR147","doi-asserted-by":"publisher","unstructured":"Carrouel F, Gon\u00e7alves LS, Conte MP, Campus G, Fisher J, Fraticelli L, et al (2020) Antiviral activity of reagents in mouth Rinses against SARS-CoV-2. J Dent Res. Oct 22:22034520967933. https:\/\/doi.org\/10.1177\/0022034520967933. Online ahead of print","DOI":"10.1177\/0022034520967933"},{"issue":"4","key":"14_CR148","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/jcm9041126","volume":"9","author":"F Carrouel","year":"2020","unstructured":"Carrouel F, Conte MP, Fisher J, Gon\u00e7alves LS, Dussart C, Llodra JC et al (2020) COVID-19: a recommendation to examine the effect of mouthrinses with \u03b2-cyclodextrin combined with citrox in preventing infection and progression. J Clin Med 9(4):1126. https:\/\/doi.org\/10.3390\/jcm9041126","journal-title":"J Clin Med"},{"issue":"2","key":"14_CR149","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.drudis.2015.11.017","volume":"21","author":"SS Jambhekar","year":"2016","unstructured":"Jambhekar SS, Breen P (2016) Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex. Drug Discov Today 21(2):356\u2013362","journal-title":"Drug Discov Today"},{"issue":"5","key":"14_CR150","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/molecules23051161","volume":"3","author":"P Saokham","year":"2018","unstructured":"Saokham P, Muankaew C, Jansook P, Loftsson T (2018) Solubility of cyclodextrins and drug\/cyclodextrin complexes. Molecules 3(5):1161. https:\/\/doi.org\/10.3390\/molecules23051161","journal-title":"Molecules"},{"issue":"5","key":"14_CR151","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/macp.201400525","volume":"216","author":"Y Pan","year":"2014","unstructured":"Pan Y, Xue Y, Snow J, Xiao H (2014) Tailor-made antimicrobial\/antiviral star polymer via ATRP of cyclodextrin and guanidine-based macromonomer. Macromol Chem Phys 216(5):511\u2013518","journal-title":"Macromol Chem Phys"},{"issue":"15","key":"14_CR152","doi-asserted-by":"publisher","first-page":"9862","DOI":"10.1128\/JVI.79.15.9862-9871.2005","volume":"79","author":"KS Choi","year":"2005","unstructured":"Choi KS, Aizaki H, Lai MMC (2005) Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J Virol 79(15):9862\u20139871","journal-title":"J Virol"},{"issue":"10","key":"14_CR153","doi-asserted-by":"publisher","first-page":"a004820","DOI":"10.1101\/cshperspect.a004820","volume":"3","author":"M Lorizate","year":"2011","unstructured":"Lorizate M, Kr\u00e4usslich HG (2011) Role of lipids in virus replication. Cold Spring Harb Perspect Biol 3(10):a004820. https:\/\/doi.org\/10.1101\/cshperspect.a004820","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"14_CR154","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbrc.2008.02.023","volume":"369","author":"Y Lu","year":"2008","unstructured":"Lu Y, Liu DX, Tam JP (2008) Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem Biophys Res Commun 369(2):344\u2013349","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"14_CR155","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.06.055","volume":"453","author":"SV Kurkov","year":"2013","unstructured":"Kurkov SV, Loftsson T (2013) Cyclodextrins. Int J Pharm 453(1):167\u2013180","journal-title":"Int J Pharm"},{"issue":"S2","key":"14_CR156","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1096\/fasebj.22.2_supplement.282","volume":"22","author":"JH Glende","year":"2008","unstructured":"Glende JH, Pfefferle S, Drosten C, Schwegmann-We\u00dfels C, Herrler G (2008) Lipid microdomains are important for the entry process of SARS coronavirus to target cells. FASEB J 22(S2):282\u2013282","journal-title":"FASEB J"},{"issue":"1","key":"14_CR157","first-page":"161","volume":"91","author":"M Baglivo","year":"2020","unstructured":"Baglivo M, Baronio M, Natalini G, Beccari T, Chiurazzi P, Fulcheri E et al (2020) Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? SARS-COV-2 lipid-dependent attachment to host cells. Acta Bio Med Atenei Parmensis 91(1):161\u2013164","journal-title":"Acta Bio Med Atenei Parmensis"},{"key":"14_CR158","unstructured":"Claude Bernard University (2020) COVID-19: Nasal and salivary detection of the SARS-CoV-2 virus after antiviral mouth rinses (BBCovid). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04352959. Accessed 31 Oct 2020"},{"issue":"8","key":"14_CR159","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00784-020-03413-2","volume":"24","author":"D Herrera","year":"2020","unstructured":"Herrera D, Serrano J, Rold\u00e1n S, Sanz M (2020) Is the oral cavity relevant in SARS-CoV-2 pandemic? Clin Oral Investig 24(8):2925\u20132930","journal-title":"Clin Oral Investig"},{"issue":"Pt 4","key":"14_CR160","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1099\/jmm.0.000034","volume":"64","author":"C Fromm-Dornieden","year":"2015","unstructured":"Fromm-Dornieden C, Rembe J-D, Sch\u00e4fer N, B\u00f6hm J, Stuermer EK (2015) Cetylpyridinium chloride and miramistin as antiseptic substances in chronic wound management - prospects and limitations. J Med Microbiol 64(Pt 4):407\u2013414","journal-title":"J Med Microbiol"},{"issue":"6","key":"14_CR161","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11095-020-02842-8","volume":"37","author":"N Baker","year":"2020","unstructured":"Baker N, Williams AJ, Tropsha A, Ekins S (2020) Repurposing quaternary ammonium compounds as potential treatments for COVID-19. Pharm Res 37(6):104. https:\/\/doi.org\/10.1007\/s11095-020-02842-8","journal-title":"Pharm Res"},{"issue":"1","key":"14_CR162","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12879-016-2177-8","volume":"17","author":"PK Mukherjee","year":"2017","unstructured":"Mukherjee PK, Esper F, Buchheit K, Arters K, Adkins I, Ghannoum MA et al (2017) Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis 17(1):74. https:\/\/doi.org\/10.1186\/s12879-016-2177-8","journal-title":"BMC Infect Dis"},{"issue":"3","key":"14_CR163","first-page":"E25","volume":"97","author":"AS Griffin","year":"2018","unstructured":"Griffin AS, Cabot P, Wallwork B, Panizza B (2018) Alternative therapies for chronic rhinosinusitis: a review. Ear Nose Throat J 97(3):E25\u2013E33","journal-title":"Ear Nose Throat J"},{"issue":"1","key":"14_CR164","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.2500\/ajra.2011.25.3583","volume":"25","author":"S Isaacs","year":"2011","unstructured":"Isaacs S, Fakhri S, Luong A, Whited C, Citardi MJ (2011) The effect of dilute baby shampoo on nasal mucociliary clearance in healthy subjects. Am J Rhinol Allergy 25(1):e27\u2013e29. https:\/\/doi.org\/10.2500\/ajra.2011.25.3583","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"14_CR165","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/alr.21116","volume":"3","author":"AA Farag","year":"2013","unstructured":"Farag AA, Deal AM, McKinney KA, Thorp BD, Senior BA, Ebert CS Jr et al (2013) Single-blind randomized controlled trial of surfactant vs hypertonic saline irrigation following endoscopic endonasal surgery. Int Forum Allergy Rhinol 3(4):276\u2013280","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"14_CR166","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2500\/ajra.2013.27.3873","volume":"27","author":"PL Rosen","year":"2013","unstructured":"Rosen PL, Palmer JN, O\u2019Malley BW, Cohen NA (2013) Surfactants in the management of rhinopathologies. Am J Rhinol Allergy 27(3):177\u2013180","journal-title":"Am J Rhinol Allergy"},{"issue":"12","key":"14_CR167","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1074\/jbc.AW118.003229","volume":"294","author":"DR Voelker","year":"2019","unstructured":"Voelker DR, Numata M (2019) Phospholipid regulation of innate immunity and respiratory viral infection. J Biol Chem 294(12):4282\u20134289","journal-title":"J Biol Chem"},{"issue":"6","key":"14_CR168","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1074\/jbc.RA119.012053","volume":"295","author":"M Numata","year":"2020","unstructured":"Numata M, Mitchell JR, Tipper JL, Brand JD, Trombley JE, Nagashima Y et al (2020) Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models. J Biol Chem 295(6):1704\u20131715","journal-title":"J Biol Chem"},{"issue":"1","key":"14_CR169","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1073\/pnas.0909361107","volume":"107","author":"M Numata","year":"2010","unstructured":"Numata M, Chu HW, Dakhama A, Voelker DR (2010) Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus\u2013induced inflammation and infection. Proc Natl Acad Sci USA 107(1):320\u2013325","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR170","doi-asserted-by":"publisher","unstructured":"Meyers C, Robison R, Milici J, Alam S, Quillen D, Goldenberg D et al (2020) Lowering the transmission and spread of human coronavirus. J Med Virol. Sep 17. https:\/\/doi.org\/10.1002\/jmv.26514. Online ahead of print","DOI":"10.1002\/jmv.26514"},{"key":"14_CR171","unstructured":"Kimura K (2020) Impact of nasal saline irrigations on viral load in patients with COVID-19. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04347538. Accessed 31 Oct 2020"},{"issue":"8","key":"14_CR172","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/alr.21959","volume":"7","author":"JH Turner","year":"2017","unstructured":"Turner JH, Wu J, Dorminy CA, Chandra RK (2017) Safety and tolerability of surfactant nasal irrigation. Int Forum Allergy Rhinol 7(8):809\u2013812","journal-title":"Int Forum Allergy Rhinol"},{"key":"14_CR173","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1146\/annurev.bi.56.070187.003455","volume":"56","author":"S Pestka","year":"1987","unstructured":"Pestka S, Langer JA, Zoon KC, Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56:727\u2013777","journal-title":"Annu Rev Biochem"},{"key":"14_CR174","doi-asserted-by":"crossref","unstructured":"De Andrea M, Ravera R, Gioia D, Gariglio M, Landolfo S (2002) The interferon system: an overview. Eur J Paediatr Neurol 6 Suppl A:A41\u201346; discussion A55\u201358","DOI":"10.1053\/ejpn.2002.0573"},{"issue":"7047","key":"14_CR175","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B et al (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047):112\u2013117","journal-title":"Nature"},{"issue":"8","key":"14_CR176","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury. Nat Med 11(8):875\u2013879","journal-title":"Nat Med"},{"key":"14_CR177","doi-asserted-by":"crossref","unstructured":"Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al (2020) SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(6):1016\u20131035.e19","DOI":"10.1016\/j.cell.2020.04.035"},{"issue":"4","key":"14_CR178","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1177\/0194599820933170","volume":"163","author":"TS Higgins","year":"2020","unstructured":"Higgins TS, Wu AW, Illing EA, Sokoloski KJ, Weaver BA, Anthony BP et al (2020) Intranasal antiviral drug delivery and coronavirus disease 2019 (COVID-19): a state of the art review. Otolaryngol Head Neck Surg 163(4):682\u2013694","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"9380","key":"14_CR179","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","volume":"362","author":"J Cinatl","year":"2003","unstructured":"Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW (2003) Treatment of SARS with human interferons. Lancet 362(9380):293\u2013294","journal-title":"Lancet"},{"issue":"10","key":"14_CR180","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s13238-017-0503-6","volume":"9","author":"Y Sun","year":"2018","unstructured":"Sun Y, Jiang J, Tien P, Liu W, Li J (2018) IFN-\u03bb: a new spotlight in innate immunity against influenza virus infection. Protein Cell 9(10):832\u2013837","journal-title":"Protein Cell"},{"key":"14_CR181","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12950-020-00249-1","volume":"17","author":"R Jiang","year":"2020","unstructured":"Jiang R, Han B, Song M, Xue B, Zhang Y, Ding Y et al (2020) Efficacy and safety of aerosol inhalation of recombinant human interferon \u03b11b (IFN\u03b11b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial. J Inflamm (Lond) 17:19. https:\/\/doi.org\/10.1186\/s12950-020-00249-1","journal-title":"J Inflamm (Lond)"},{"issue":"2","key":"14_CR182","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1164\/rccm.201312-2235OC","volume":"190","author":"R Djukanovi\u0107","year":"2014","unstructured":"Djukanovi\u0107 R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC et al (2014) The effect of inhaled IFN-\u03b2 on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 190(2):145\u2013154","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"14_CR183","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1631\/jzus.B2000211","volume":"21","author":"SR Hao","year":"2020","unstructured":"Hao SR, Yan R, Zhang SY, Lian JS, Cai H, Zhang XL et al (2020) Interferon-alpha2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. J Zhejiang Univ Sci B 21(8):628\u2013636","journal-title":"J Zhejiang Univ Sci B"},{"key":"14_CR184","doi-asserted-by":"publisher","unstructured":"Meng Z, Wang T, Li C, Chen X, Li L, Qin X et al (2020) An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv. https:\/\/doi.org\/10.1101\/2020.04.11.20061473","DOI":"10.1101\/2020.04.11.20061473"}],"container-title":["Advances in Experimental Medicine and Biology","Identification of Biomarkers, New Treatments, and Vaccines for COVID-19"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-71697-4_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T06:03:42Z","timestamp":1699250622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-71697-4_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030716967","9783030716974"],"references-count":185,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-71697-4_14","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"20 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}